Clinical Trial Update: Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing lisdexamfetamine for ADHD and related SCT has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Disorder
• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Lisdexamfetamine (lisdexamfetamine dimesylate)

Snippet

Sponsor: NYU Langone Health | Conditions: Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED | Results posted: 2021-11-16